EICHOR
● Completed
Treatment Patterns & Clinical Outcomes of Palbociclib Combinations in HR+HER2-MBC
Condition: Metastatic Breast Cancer · Sponsor: Pfizer
About this study
The objective of this non-interventional multicenter study is to provide prospective, observational data on patients initiating treatment with palbociclib combination to contribute to the knowledge of HR+ HER2-metastatic/locally advanced Breast Cancer (BC) disease management, its treatment pattern, clinical outcomes and quality of life (QoL) in the routine clinical practice in Africa and Middle East countries .
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (12)
| Alexandria School of Medicine/Clinical Research Center CRC | Alexandria, Egypt | — |
| Dar El Salam Oncology Hospital | Cairo, Egypt | — |
| National Cancer Institute | Cairo, Egypt | — |
| Ain Shams University Hospital | Cairo, Egypt | — |
| King Hussein Cancer Center | Amman, Jordan | — |
| American University of Beirut Medical Center | Beirut, Lebanon | — |
| Hôtel Dieu de France (HDF) | Beirut, Lebanon | — |
| Saint Joseph Hospital - Cancer Centers of Colorado | Jdeidé - Metn, Lebanon | — |
| Hammoud Hospital University Medical Center (HHUMC) | Sidon, Lebanon | — |
| Hamad Medical Corporation | Doha, Qatar | — |
| King Fahad Specialist Hospital KFSH-Dammam | Dammam, Saudi Arabia | — |
| National Guard Hospital, Riyadh | Riyadh, Saudi Arabia | — |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04937660